GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » Price-to-Tangible-Book

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Price-to-Tangible-Book : 3.94 (As of Apr. 30, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-30), Cumberland Pharmaceuticals's share price is $1.70. Cumberland Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.43. Hence, Cumberland Pharmaceuticals's Price to Tangible Book Ratio of today is 3.94.

The historical rank and industry rank for Cumberland Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

CPIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.55   Med: 3.27   Max: 6.8
Current: 3.95

During the past 13 years, Cumberland Pharmaceuticals's highest Price to Tangible Book Ratio was 6.80. The lowest was 1.55. And the median was 3.27.

CPIX's Price-to-Tangible-Book is ranked worse than
71.07% of 871 companies
in the Drug Manufacturers industry
Industry Median: 2.34 vs CPIX: 3.95

A closely related ratio is called PB Ratio. As of today, Cumberland Pharmaceuticals's share price is $1.70. Cumberland Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.10. Hence, Cumberland Pharmaceuticals's P/B Ratio of today is 0.81.


Cumberland Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Cumberland Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals Price-to-Tangible-Book Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.07 2.46 3.83 6.80 4.16

Cumberland Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.80 4.64 2.64 3.38 4.16

Competitive Comparison of Cumberland Pharmaceuticals's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Price-to-Tangible-Book falls into.



Cumberland Pharmaceuticals Price-to-Tangible-Book Calculation

Cumberland Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=1.70/0.431
=3.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Cumberland Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Executives
Todd M. Anthony officer: Vice Pres Organizational Dev 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman officer: Vice Pres Sales & Marketing 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante director 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones director 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr director 850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi director, 10 percent owner, officer: Chairman and CEO 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal director 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard officer: Senior Vice President 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs director 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence director 1880 ELLINGTON WAY, AUBURN AL 36830